Brand · Injection
Procrit 2000 units/mL, 1 mL injection price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for procrit 2000 units/ml, 1 ml injection this week. The makers, package codes, recalls and label are below.
What people paid for procrit 2000 units/ml, 1 ml injection
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Recalls
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
1 company sell procrit 2000 units/ml, 1 ml injection under 1 package code (NDC).
| Maker | Package codes | Per unit |
|---|---|---|
| Janssen Products, LP | 59676-302-01 | - |
All 1 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other procrit strengths and forms
| Strength and form | Per unit | Pharmacies pay | ||
|---|---|---|---|---|
| 3000 units/mL, 1 mL injection Brand | Not priced this week | |||
| 4000 units/mL, 1 mL injection Brand | $104.28 | $625.69 / 6 mL | ||
| 10000 units/mL, 1 mL injection Brand | $259.94 | $1,559.67 / 6 mL | ||
| 20000 units/mL injection Brand | $521.36 | $2,085.44 / 4 mL | ||
| 40000 units/mL, 1 mL injection Brand | $1,038.70 | $4,154.80 / 4 mL | ||
Official label & what changed
These highlights do not include all the information needed to use PROCRIT safely and effectively. See full prescribing information for PROCRIT. PROCRIT ®(epoetin alfa) injection, for intravenous or subcutaneous use Initial U.S. Approval: 1989
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
WARNING: ESAs INCREASE THE RISK OF DEATH, MYOCARDIAL INFARCTION, STROKE, VENOUS THROMBOEMBOLISM, THROMBOSIS OF VASCULAR ACCESS AND TUMOR PROGRESSION OR RECURRENCE
See full prescribing information for complete boxed warning.
Chronic Kidney Disease:
In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL (
5.1).
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks (
2.2).
Use the lowest PROCRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions (
5.1).
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers (
5.2).
Use the lowest dose to avoid RBC transfusions (
2.4).
Use ESAs only for anemia from myelosuppressive chemotherapy (
1.3).
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure (
1.5).
Discontinue following the completion of a chemotherapy course (
2.4).
Perisurgery:
Due to increased risk of deep venous thrombosis (DVT), DVT prophylaxis is recommended (
5.1).
Chronic Kidney Disease:
In controlled trials, patients with chronic kidney disease (CKD) experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL[see
Warnings and Precautions (5.1)]
.
No trial has identified a hemoglobin target level, ESA dose, or dosing strategy that does not increase these risks[see
Dosage and Administration (2.2)]
.
Use the lowest PROCRIT dose sufficient to reduce the need for red blood cell (RBC) transfusions[see
Warnings and Precautions (5.1)]
.
Cancer:
ESAs shortened overall survival and/or increased the risk of tumor progression or recurrence in clinical studies of patients with breast, non-small cell lung, head and neck, lymphoid, and cervical cancers[see
Warnings and Precautions (5.2)]
.
To decrease these risks, as well as the risk of serious cardiovascular and thromboembolic reactions, use the lowest dose needed to avoid RBC transfusions
[see
Dosage and Administration (2.4)]
.
Use ESAs only for anemia from myelosuppressive chemotherapy[see
Indications and Usage (1.3)]
.
ESAs are not indicated for patients receiving myelosuppressive chemotherapy when the anticipated outcome is cure[see
Indications and Usage (1.5)]
.
Discontinue following the completion of a chemotherapy course[see
Dosage and Administration (2.4)]
.
Perisurgery:
Due to increased risk of Deep Venous Thrombosis (DVT), DVT prophylaxis is recommended[see
Dosage and Administration (2.5),
Warnings and Precautions (5.1)]
.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about procrit 2000 units/ml, 1 ml injection
Who makes procrit 2000 units/ml, 1 ml injection?
1 company: Janssen Products, LP. See every package code.
Is procrit in shortage?
No shortage is reported right now. We check every day.
Has procrit been recalled?
3 recalls on record. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about procrit 2000 units/ml, 1 ml injection
No comments yet. Questions, tips, what worked for you - start the conversation.